Fig. 3: The emerging roles of CRISPR-Cas13 in regulating m6A in cancer.
From: Emerging implications of N6-methyladenosine in prostate cancer progression and treatment
In various cancer models—including lung cancer, acute myeloid leukemia (AML), and chronic kidney disease (CKD)—the expression of downstream molecules is influenced by targeting m6A regulators or m6A modifications. It is therefore reasonable to hypothesize that related epigenetic changes, both in vivo and in vitro, can be detected using CRISPR-Cas13–based systems.
